High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas

Research output: Contribution to journalArticle

Standard

High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. / Schrader, Alexandra; Bentink, Stefan; Spang, Rainer; Lenze, Dido; Hummel, Michael; Kuo, Michael; Arrand, John R; Murray, Paul G; Trümper, Lorenz; Kube, Dieter; Vockerodt, Martina.

In: International Journal of Cancer, Vol. 131, No. 4, 15.08.2012, p. E348-61.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Schrader, Alexandra ; Bentink, Stefan ; Spang, Rainer ; Lenze, Dido ; Hummel, Michael ; Kuo, Michael ; Arrand, John R ; Murray, Paul G ; Trümper, Lorenz ; Kube, Dieter ; Vockerodt, Martina. / High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. In: International Journal of Cancer. 2012 ; Vol. 131, No. 4. pp. E348-61.

Bibtex

@article{3c500fa92c3f4a8da9b256c123b6eb57,
title = "High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas",
abstract = "Gene expression profiling has recently enabled the reclassification of aggressive non-Hodgkin lymphomas (aNHL) into distinct subgroups. In Burkitt lymphoma (BL) aberrant c-Myc activity results from IG-MYC translocations. However, MYC aberrations are not limited to BLs and then have a negative prognostic impact. In this study, we investigated to which extent aberrant c-Myc activity plays a functional role in other aNHL and whether it is independent from MYC translocations. Based on a combined microarray analysis of human germinal center (GC) B cells transfected with c-Myc and 220 aNHLs cases, we developed a {"}c-Myc index.{"} This index measures the extent to which lymphomas express c-Myc responsive genes. It comprises genes that are affected in a variety of tumors compared to normal tissue. This supports the view that aberrant c-Myc expression in GC B cells triggers a tumor-like expression pattern. As expected, the {"}c-Myc index{"} is very high in molecular Burkitt lymphoma (mBL), but more importantly also high within other aNHL. It constitutes a negative prognostic marker independent of established risk factors and of the presence of a MYC translocation. Our data provide new insights into the role of c-Myc activity in different lymphomas and raises the question of treatment changes for those patients under risk.",
author = "Alexandra Schrader and Stefan Bentink and Rainer Spang and Dido Lenze and Michael Hummel and Michael Kuo and Arrand, {John R} and Murray, {Paul G} and Lorenz Tr{\"u}mper and Dieter Kube and Martina Vockerodt",
note = "Copyright {\textcopyright} 2011 UICC.",
year = "2012",
month = aug,
day = "15",
doi = "10.1002/ijc.26423",
language = "English",
volume = "131",
pages = "E348--61",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley",
number = "4",

}

RIS

TY - JOUR

T1 - High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas

AU - Schrader, Alexandra

AU - Bentink, Stefan

AU - Spang, Rainer

AU - Lenze, Dido

AU - Hummel, Michael

AU - Kuo, Michael

AU - Arrand, John R

AU - Murray, Paul G

AU - Trümper, Lorenz

AU - Kube, Dieter

AU - Vockerodt, Martina

N1 - Copyright © 2011 UICC.

PY - 2012/8/15

Y1 - 2012/8/15

N2 - Gene expression profiling has recently enabled the reclassification of aggressive non-Hodgkin lymphomas (aNHL) into distinct subgroups. In Burkitt lymphoma (BL) aberrant c-Myc activity results from IG-MYC translocations. However, MYC aberrations are not limited to BLs and then have a negative prognostic impact. In this study, we investigated to which extent aberrant c-Myc activity plays a functional role in other aNHL and whether it is independent from MYC translocations. Based on a combined microarray analysis of human germinal center (GC) B cells transfected with c-Myc and 220 aNHLs cases, we developed a "c-Myc index." This index measures the extent to which lymphomas express c-Myc responsive genes. It comprises genes that are affected in a variety of tumors compared to normal tissue. This supports the view that aberrant c-Myc expression in GC B cells triggers a tumor-like expression pattern. As expected, the "c-Myc index" is very high in molecular Burkitt lymphoma (mBL), but more importantly also high within other aNHL. It constitutes a negative prognostic marker independent of established risk factors and of the presence of a MYC translocation. Our data provide new insights into the role of c-Myc activity in different lymphomas and raises the question of treatment changes for those patients under risk.

AB - Gene expression profiling has recently enabled the reclassification of aggressive non-Hodgkin lymphomas (aNHL) into distinct subgroups. In Burkitt lymphoma (BL) aberrant c-Myc activity results from IG-MYC translocations. However, MYC aberrations are not limited to BLs and then have a negative prognostic impact. In this study, we investigated to which extent aberrant c-Myc activity plays a functional role in other aNHL and whether it is independent from MYC translocations. Based on a combined microarray analysis of human germinal center (GC) B cells transfected with c-Myc and 220 aNHLs cases, we developed a "c-Myc index." This index measures the extent to which lymphomas express c-Myc responsive genes. It comprises genes that are affected in a variety of tumors compared to normal tissue. This supports the view that aberrant c-Myc expression in GC B cells triggers a tumor-like expression pattern. As expected, the "c-Myc index" is very high in molecular Burkitt lymphoma (mBL), but more importantly also high within other aNHL. It constitutes a negative prognostic marker independent of established risk factors and of the presence of a MYC translocation. Our data provide new insights into the role of c-Myc activity in different lymphomas and raises the question of treatment changes for those patients under risk.

U2 - 10.1002/ijc.26423

DO - 10.1002/ijc.26423

M3 - Article

C2 - 21913186

VL - 131

SP - E348-61

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -